cbdMD Inc
AMEX: YCBD · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-10-28
cbdMD Inc (YCBD) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for YCBD.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
YCBD historical valuation range
Where current P/E sits in YCBD's own 5Y range.
YCBD intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
YCBD valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 1.58x
P/S Ratio — History
Current: 0.19x
Is YCBD overvalued in 2026?
cbdMD Inc (YCBD) currently trades at $0.37 per share with a market capitalization of $4,062,900.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 39/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 1.6x, above its 5-year median of 1.4x.
Looking at its own history, YCBD is currently trading more expensive than 71% of the last 5Y on P/E. This places it in the 71th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates YCBD's intrinsic value at $0.79 per share, against the current market price of $0.37. This implies a margin of safety of +4.59%. The stock is priced close to its estimated fair value, offering limited upside without further operational improvement.
The Piotroski F-Score of 6/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: YCBD appears richly valued on our framework, with a Smart Value Score of 39/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is YCBD overvalued?
YCBD scores 39/100 on our Smart Value Score (Grade D), a weak overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is YCBD's fair value?
Our DCF model estimates YCBD's intrinsic value at $0.79 per share, versus the current price of $0.37, a margin of safety of +4.59%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does YCBD trade at?
YCBD trades at a P/E of 1.6x on trailing twelve-month earnings, against a 5-year median of 1.4x. P/E is what you pay per dollar of profit, and sitting above its own median means the stock is pricier than usual relative to its earnings.
Is YCBD a buy based on valuation?
Our Smart Value rating for YCBD is Sell, from a Smart Value Score of 39/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does YCBD's valuation compare to its history?
On P/E, YCBD sits in the 71st percentile of its own 5Y range, above its long-run median relative to where it has traded. A high percentile means today's multiple is near the top of its historical band.
What is YCBD's Smart Value Score?
YCBD's Smart Value Score is 39/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.